Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Bionano Genomics, Inc. (BNGO)
|
Add to portfolio |
|
|
|
| Price: |
$3.11
| | Metrics |
| OS: |
35.3
|
M
| |
|
|
| Market cap: |
$110
|
M
| |
|
|
|
Net cash:
|
$77.1
|
M
| |
$2.18
|
per share
|
|
EV:
|
$32.9
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 27.8 | 18.0 | 8.5 | 10.1 | 12.0 | 9.5 | 18.2 |
| Revenue growth | 54.6% | 111.5% | -16.1% | -15.6% | 26.3% | -47.8% | |
| Cost of goods sold | 21.9 | 14.1 | 5.7 | 6.8 | 8.7 | 6.0 | 3.6 |
| Gross profit | 5.9 | 3.9 | 2.8 | 3.4 | 3.3 | 3.5 | 14.6 |
| Gross margin | 21.4% | 21.5% | 32.6% | 33.2% | 27.4% | 36.6% | 80.4% |
| Selling, general and administrative | 88.6 | 58.5 | 31.1 | 20.2 | 14.2 | 14.1 | 13.0 |
| Research and development | 49.0 | 22.5 | 10.3 | 9.1 | 9.5 | 12.0 | |
| EBITA | -125.9 | -75.7 | -38.5 | -25.9 | -20.4 | -22.6 | -21.2 |
| EBITA margin | -452.8% | -421.0% | -452.2% | -255.4% | -170.1% | -237.9% | -116.2% |
| Amortization of intangibles | 5.8 | 1.4 | 0.1 | | | | |
| EBIT | -131.7 | -77.1 | -38.6 | -25.9 | -20.4 | -22.6 | -21.2 |
| EBIT margin | -473.7% | -428.8% | -453.4% | -255.4% | -170.1% | -237.9% | -116.2% |
| Pre-tax income | -130.7 | -78.2 | -41.1 | -29.8 | -18.5 | -23.3 | -18.8 |
| Income taxes | 1.9 | -5.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 7.3% | | | | | 0.1% |
| Net income | -132.6 | -72.4 | -41.1 | -29.8 | -18.5 | -23.4 | 0.0 |
| Net margin | -476.9% | -402.8% | -483.4% | -294.3% | -154.1% | -245.8% | 0.0% |
| |
| Diluted EPS | ($0.46) | ($0.26) | ($0.39) | ($1.99) | ($2.61) | ($8.65) | $0.00 |
| Shares outstanding (diluted) | 289.2 | 276.8 | 104.3 | 15.0 | 7.1 | 2.7 | 60.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|